Crinetics Announced Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
Portfolio Pulse from Charles Gross
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced positive results from the Phase 3 PATHFNDR-1 study of paltusotine, an oral, once-daily investigational compound for the treatment of acromegaly. The study met its primary endpoint and all secondary endpoints, showing statistical significance.
September 10, 2023 | 2:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Crinetics Pharmaceuticals' successful Phase 3 study results for paltusotine could potentially boost the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, potentially driving up the stock price. As the company behind the successful trial, Crinetics Pharmaceuticals stands to benefit from this positive news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100